INMB · XBRL financial data

Inmune Bio financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (INMB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	11	181	374	155	14	50
Research and development	5,917	20,543	17,067	20,273	33,166	20,659
General and administrative	6,321	8,791	9,258	9,623	9,483	10,260
Total operating expenses	12,239	29,334	26,325	29,896	42,649	47,433
Other operating income (expense)	129	(1,187)	(1,348)	—	—	—
Operating income (loss)	(12,228)	(29,153)	(25,951)	(29,741)	(42,635)	(47,383)
Interest expense	—	985	2,014	2,278	789	0
Other income (expense)	129	—	(1,348)	(267)	553	—
Net income (loss)	(12,099)	(30,340)	(27,299)	(30,008)	(42,082)	(45,933)
Earnings per share, basic USD per share	—	(1.88)	(1.52)	(1.67)	(2.11)	(1.86)
Earnings per share, diluted USD per share	—	(1.88)	(1.52)	(1.67)	(2.11)	(1.86)
Weighted average shares, basic thousands of shares	—	16,131	17,927	17,981	19,944	24,758
Weighted average shares, diluted thousands of shares	—	16,131	17,927	17,981	19,944	24,758

Fiscal years (INMB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	21,967	74,810	52,153	35,848	20,922	24,751
Accounts receivable	—	—	—	1,905	1,181	4,284
Prepaid and other current assets	—	14	34	1,510	331	595
Total current assets	23,986	82,606	64,675	39,942	22,662	29,887
Property and equipment, net	—	—	—	—	—	955
Right-of-use asset	156	726	507	414	307	914
Total assets	40,656	99,945	81,795	57,001	39,562	32,351
Current portion of long-term debt	—	—	5,000	9,921	—	—
Total current liabilities	1,776	4,359	10,918	18,465	7,221	8,416
Long-term debt	—	—	9,697	—	—	—
Lease liability, non-current	126	704	526	397	244	411
Total liabilities	1,903	19,720	21,691	18,862	7,465	8,827
Accumulated deficit	(33,375)	(63,715)	(91,014)	(121,022)	(163,104)	(209,037)
Total stockholders' equity	38,753	80,225	60,104	37,340	32,097	23,524
Total liabilities and equity	40,656	99,945	81,795	57,001	39,562	32,351
Common shares outstanding (cover page) thousands of shares	14,933	17,704	17,946	18,026	22,930	26,585

Fiscal years (INMB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(12,099)	(30,340)	(27,299)	(30,008)	(42,082)	(45,933)
Stock-based compensation	3,112	4,796	7,149	7,368	7,605	9,910
Net cash from operating activities	(8,944)	(28,504)	(22,686)	(11,980)	(33,361)	(22,582)
Purchases of property and equipment	—	—	—	—	—	1,042
Net cash from investing activities	—	(15,000)	—	—	—	(1,042)
Proceeds from issuing common stock	24,908	80,253	699	775	27,789	27,544
Net cash from financing activities	23,896	96,357	729	(4,225)	18,211	27,612
Net change in cash	—	52,843	(22,657)	(16,305)	(14,926)	3,829

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Inmune Bio	18,411	not reported	(3,175)*	27.8M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	85,382	not reported	(19,988)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.